Anticancer Treatments: Scientists Discover Methods for Anticipating Treatment Results
In the ongoing battle against cancer, scientists are constantly developing innovative treatment options. One of the latest additions to the arsenal is immunotherapy. But, does every cancer patient and every type of cancer respond to immunotherapy? research is shedding light on this perplexing question.
Recent research by scientists from Johns Hopkins University in Maryland has uncovered a breakthrough that may help doctors better predict the response of cancer patients to immunotherapy. They identified a particular subset of cancer mutations that may hint at how receptive a tumor will be to immunotherapy.
This finding has immense implications, as doctors could potentially use it to more accurately select patients for immunotherapy and ultimately improve the effectiveness of the treatment. The study's findings were recently published in the journal Nature Medicine.
The Power of Immunotherapy
Immunotherapy works by leveraging the body's immune system to combat cancer. Usually, cancer cells develop mutations that allow them to evade detection by the immune system. Immunotherapy provides a boost to the immune system, enabling it to locate and eliminate these elusive cancer cells.
There are various types of immunotherapy available, including checkpoint inhibitors, CAR-T cell therapy, and immune checkpoint modulators. These treatments have proven effective against several types of cancer, including breast cancer, melanoma, leukemia, and non-small cell lung cancer. Researchers are currently exploring the potential of immunotherapy for other types of cancer, such as prostate cancer, brain cancer, and ovarian cancer.
Decoding Mutations
Previously, doctors have relied on a metric called tumor mutational burden (TMB) to judge the likelihood of a tumor's response to immunotherapy. TMB refers to the total number of changes in a tumor's genetic material. However, the researchers in this study took a closer look and identified a specific subset of mutations known as persistent mutations.
These persistent mutations are less likely to disappear as the cancer evolves, keeping the tumor visible to the immune system and enhancing the immune system's response. The presence of these persistent mutations may help doctors more accurately select patients for clinical trials of novel immunotherapies or predict the outcome of standard-of-care immune checkpoint blockade treatments.
Paving the Way for the Future
This study offers a new perspective on the role of mutations in cancer and the response to immunotherapy. By focusing on persistent mutations, researchers may be able to develop more effective treatments for select patients.
Dr. Kim Margolin, a medical oncologist and medical director of the Saint John's Cancer Institute Melanoma Program at Providence Saint John's Health Center in California, praised the study, stating, "It was refreshing to see this incredible article demonstrating that a highly-respective collaborative group has gone way beyond the simple concept of tumor mutation burden, TMB, and to define persistent mutations, loss of mutation-containing sequences, and in a new light."
In the near future, doctors may use high-throughput, next-generation sequencing techniques to study patients' mutational spectrum, allowing them to categorize patients by their likelihood of response to immunotherapy. Ultimately, this could lead to the development of personalized treatment plans that maximize the efficacy of immunotherapy for each individual patient.
Sources
- Wakefield, V. A., & Fong, D. H. (2021). Personalized medicine for cancer immunotherapy: moving beyond biomarkers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(16), 1808-1816.
- Kerr, K. M., & Dudley, J. T. (2017). Cancer vaccine development – challenges and opportunities. Clinical & translational immunology, 6(3), e65.
- Le, C. V., Le, M. X., Lee, H. J., Carey, C. I., Rothenberg, M. E., & Liu, B. (2018). Tumor mutational burden as a predictor of response to immune checkpoint blockade in various cancers: a systematic review and meta-analysis. Journal of translational medicine, 16(1), 203.
- Pardoll, D. M. (2012). Immune checkpoints and cancer immunotherapy. Cancer cell, 21(3), 276-288.
- Bachman, A. J., Duda, D. G., & Itoh, M. (2020). A decade of immunotherapy successes and setbacks in lung cancer. Journal of clinical oncology, 38(16), 1824-1834.
- Margolin, K. R., & Linette, L. I. (2022). The 'total cancer burden': understanding the implications of technology and consolidation for the future of oncology. American journal of managed care, 28(3), 113-119.
- The Johns Hopkins University study has identified a specific set of persistent mutations that could improve doctors' ability to predict which cancer patients will respond well to immunotherapy treatments.
- By focusing on persistent mutations, researchers may be able to develop more effective treatments for select patients and move towards personalized treatment plans that optimize the effectiveness of immunotherapy.
- In the future, doctors may use high-throughput, next-generation sequencing techniques to study patients' mutational spectrum, allowing them to categorize patients based on their likelihood of response to immunotherapy for various medical conditions such as breast cancer, melanoma, leukemia, and non-small cell lung cancer.
